Selection of genes differentially expressed in HSTL primary tumors compared with normal γδ T cells (P < .01)
| Genes overexpressed in HSTL compared with normal γδ T cells (P < .01) . | ||
|---|---|---|
| Gene class and specific genes . | Fold change . | |
| Activated . | Resting . | |
| Oncogenes | ||
| FOS* | 6.50 | |
| VAV3† | 3.52 | 3.67 |
| MAF | 4.42 | |
| NK-cell–associated molecules | ||
| KIR2DS2*† | 13.98 | 16.63 |
| KLRC3*† | 11.33 | 14.87 |
| KIR3DL1//KIR3DL2*† | 9.56 | 11.16 |
| KIR2DL1*† | 8.90 | 7.57 |
| KIR2DL2*† | 8.60 | 8.85 |
| KIR2DS5*† | 7.26 | 5.19 |
| KIR3DS1*† | 7.03 | 6.34 |
| KIR2DL3*† | 6.83 | 9.06 |
| KIR2DL5A*† | 6.40 | 6.09 |
| KIR3DL3*† | 5.75 | 6.51 |
| KLRC4*† | 5.70 | 5.17 |
| KIR2DS3*† | 5.69 | 6.34 |
| KIR2DS1*† | 5.00 | 5.17 |
| KIR2DS4*† | 3.23 | 3.67 |
| CD244* | 7.23 | 3.18 |
| NCAM1* | 6.27 | |
| Microenvironment | ||
| Hemoglobin beta | 46.31 | 34.14 |
| Hemoglobin alpha | 34.93 | 24.06 |
| CXCL12 | 31.57 | 27.39 |
| Immunoglobulin | 26.29 | 21.08 |
| CD163 | 8.86 | |
| Signal transduction | ||
| SPRY2*† | 13.77 | 33.98 |
| RHOB*† | 7.03 | |
| MAP4K3*† | 5.96 | 9.18 |
| SPRY1*† | 6.50 | 7.97 |
| Sonic hedgehog | ||
| GLI3* | 8.86 | 5.94 |
| PRKAR2B* | 8.25 | 3.15 |
| PRKACB† | 3.25 | 3.75 |
| PRKAR1A† | 2.80 | 7.63 |
| Tyrosine kinase | ||
| SYK* | 10.59 | 2.68 |
| Cell adhesion | ||
| CD11d*† | 37.57 | 33.11 |
| VCAM1 | 15.06 | 71.58 |
| ICAM1 | 5.71 | |
| Wnt pathways | ||
| FRZB | 14.01 | 14.19 |
| TCF7L2* | 10.96 | |
| BAMBI | 8.58 | 7.52 |
| TLE1* | 7.16 | 4.48 |
| CTNNB1* | 3.99 | 11.24 |
| APC | 3.60 | 2.33 |
| FZD5 | 2.53 | 3.43 |
| Others | ||
| S1PR5* | 8.16 | 3.51 |
| Genes overexpressed in HSTL compared with normal γδ T cells (P < .01) . | ||
|---|---|---|
| Gene class and specific genes . | Fold change . | |
| Activated . | Resting . | |
| Oncogenes | ||
| FOS* | 6.50 | |
| VAV3† | 3.52 | 3.67 |
| MAF | 4.42 | |
| NK-cell–associated molecules | ||
| KIR2DS2*† | 13.98 | 16.63 |
| KLRC3*† | 11.33 | 14.87 |
| KIR3DL1//KIR3DL2*† | 9.56 | 11.16 |
| KIR2DL1*† | 8.90 | 7.57 |
| KIR2DL2*† | 8.60 | 8.85 |
| KIR2DS5*† | 7.26 | 5.19 |
| KIR3DS1*† | 7.03 | 6.34 |
| KIR2DL3*† | 6.83 | 9.06 |
| KIR2DL5A*† | 6.40 | 6.09 |
| KIR3DL3*† | 5.75 | 6.51 |
| KLRC4*† | 5.70 | 5.17 |
| KIR2DS3*† | 5.69 | 6.34 |
| KIR2DS1*† | 5.00 | 5.17 |
| KIR2DS4*† | 3.23 | 3.67 |
| CD244* | 7.23 | 3.18 |
| NCAM1* | 6.27 | |
| Microenvironment | ||
| Hemoglobin beta | 46.31 | 34.14 |
| Hemoglobin alpha | 34.93 | 24.06 |
| CXCL12 | 31.57 | 27.39 |
| Immunoglobulin | 26.29 | 21.08 |
| CD163 | 8.86 | |
| Signal transduction | ||
| SPRY2*† | 13.77 | 33.98 |
| RHOB*† | 7.03 | |
| MAP4K3*† | 5.96 | 9.18 |
| SPRY1*† | 6.50 | 7.97 |
| Sonic hedgehog | ||
| GLI3* | 8.86 | 5.94 |
| PRKAR2B* | 8.25 | 3.15 |
| PRKACB† | 3.25 | 3.75 |
| PRKAR1A† | 2.80 | 7.63 |
| Tyrosine kinase | ||
| SYK* | 10.59 | 2.68 |
| Cell adhesion | ||
| CD11d*† | 37.57 | 33.11 |
| VCAM1 | 15.06 | 71.58 |
| ICAM1 | 5.71 | |
| Wnt pathways | ||
| FRZB | 14.01 | 14.19 |
| TCF7L2* | 10.96 | |
| BAMBI | 8.58 | 7.52 |
| TLE1* | 7.16 | 4.48 |
| CTNNB1* | 3.99 | 11.24 |
| APC | 3.60 | 2.33 |
| FZD5 | 2.53 | 3.43 |
| Others | ||
| S1PR5* | 8.16 | 3.51 |
| Genes down-regulated in HSTL compared with normal γδ T cells (P < .01) . | ||
|---|---|---|
| Cytotoxic molecules | ||
| Granulysin*† | 0.03 | 0.03 |
| Granzyme H*† | 0.03 | 0.05 |
| Granzyme B* | 0.04 | 0.17 |
| Granzyme K*† | 0.26 | 0.10 |
| Chemokines | ||
| LTA* | 0.02 | |
| TNF | 0.03 | |
| IFNG* | 0.03 | |
| Tumor suppressor | ||
| AIM1*† | 0.34 | 0.24 |
| Others | ||
| CD5*† | 0.24 | 0.20 |
| Genes down-regulated in HSTL compared with normal γδ T cells (P < .01) . | ||
|---|---|---|
| Cytotoxic molecules | ||
| Granulysin*† | 0.03 | 0.03 |
| Granzyme H*† | 0.03 | 0.05 |
| Granzyme B* | 0.04 | 0.17 |
| Granzyme K*† | 0.26 | 0.10 |
| Chemokines | ||
| LTA* | 0.02 | |
| TNF | 0.03 | |
| IFNG* | 0.03 | |
| Tumor suppressor | ||
| AIM1*† | 0.34 | 0.24 |
| Others | ||
| CD5*† | 0.24 | 0.20 |